Current status: The Oral GLP-1 Tracker: Lilly takes time to build awareness for Foundayo as generic tirzepatide looms

Approximately three months after an FDA approval that generated a lot of excitement, demand for Eli Lilly’s GLP-1 obesity pill, Foundayo (orforglipron), has grown steadily but remains relatively modest so far, with around 20,000 people using the drug and roughly 5,600 prescriptions in its third week on the market, suggesting a slow build rather than a launch surge. The convenience advantage—once‑daily oral dosing with no food or water restrictions—has helped it gain traction, but it is still trailing established injectables such as tirzepatide (Zepbound) on weight‑loss efficacy and market visibility. Lilly has been rolling out commercial and medical‑education campaigns, emphasizing trial data showing meaningful weight loss and A1C control in diabetes, while positioning Foundayo as a needle‑free option for patients reluctant to inject.
However, the picture is beginning to tilt toward generic competition, as key patents on tirzepatide are expected to expire in the U.S. in the coming years, and industry analysts anticipate that a generic tirzepatide could enter the market in the early‑2030s. In that context, the slower uptake of Foundayo reflects not only a maturing oral GLP‑1 category but also provider and patient expectations that eventually they may access a lower‑cost, higher‑efficacy injectable once tirzepatide goes off patent. Lilly’s strategy appears to be to build brand awareness and clinical experience for Foundayo now, reinforcing its role as a convenient, flexible alternative while the broader market waits for the first generic tirzepatide wave.